Vanda Pharmaceuticals (VNDA-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr03/2026	Next Qtr06/2026	Fiscal Yr12/2026	Fiscal Yr12/2027
Average Estimate	-0.53	-0.51	-2.18	-0.71
Number of Estimates	2	2	4	3
High Estimate	-0.49	-0.51	-1.65	-0.43
Low Estimate	-0.57	-0.51	-2.79	-1.16
Prior Year	-0.50	-0.46	-1.81	-2.18
Growth Rate Est. (year over year)	-6.00%	-10.87%	-20.44%	+67.43%

Earnings History - Surprises*

	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025	Qtr Ending03/2025
Reported	$-0.46	$-0.38	$-0.46	$-0.50
Estimate	$-2.18	$-0.31	$-0.34	$-0.55
Difference	+1.72	-0.07	-0.12	+0.05
Surprise	+78.90%	-22.58%	-35.29%	+9.09%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

4.20

3 Mths Ago5

4.20

2 Mths Ago5

4.20

1 Mth Ago5

4.33

Current6

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	5	5	5	6
	3	3	3	4
Holds	2	2	2	2

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Wednesday’s analyst upgrades and downgrades

Bullish on Archer-Daniels-Midland Co.

Constellation ‘well-positioned’ to tackle AI disruption in software industry, company president says

number cruncher

Eight telecom stocks to watch during volatile times

The most oversold and overbought stocks on the TSX

Analysts’ forecast returns, recommendations and yields for all stocks in the S&P/TSX SmallCap Index

Small caps to watch: Aecon, Maple Leaf Foods, Tecsys and more

Thursday’s analyst upgrades and downgrades